Nevertheless, tumor cells increased PD-L1 expression and decreased anti-tumor cytokine production, suggesting that TAT would be effective in combination with anti-PD-L1 immunotherapy which is allowed by the possible stable linking of biomolecules such as antibodies on 213Bi (mixed alpha/beta emitter) and 225AC (pure alpha emitter) through their trivalent metal ions forms. Here, CD274 is linked to neoplasm.